Value of a genetics clinic evaluation in identifying women at risk for hereditary breast‐ovarian cancer syndrome

Author(s):  
Jesse C. Hinshaw ◽  
Lue‐Ping Zhao ◽  
John E. Brimm ◽  
Thomas H. Payne ◽  
Fuki M. Hisama
2000 ◽  
Vol 79 (3) ◽  
pp. 477-481 ◽  
Author(s):  
Ran Goshen ◽  
William Chu ◽  
Laurie Elit ◽  
Tuya Pal ◽  
Jalil Hakimi ◽  
...  

2020 ◽  
Vol 29 (4) ◽  
pp. 681-687
Author(s):  
Natalia Campacci ◽  
Henrique Campos Reis Galvão ◽  
Lucas F. Garcia ◽  
Paula C. Ribeiro ◽  
Rebeca S. Grasel ◽  
...  

1993 ◽  
Vol 79 (5) ◽  
pp. 291-296 ◽  
Author(s):  
Simon A. Smith ◽  
Bruce A.J. Ponder

The isolation of genes that predispose to familial disease is an important goal in cancer research. The identification of such genes « opens up » the possibility of genetic diagnosis in families so that individuals who are at risk of cancer through inheriting a predisposing mutation can be Identified. Genes that are involved in familial cancer syndromes may also be important in the pathogenesis of sporadic forms of the disease, which are often more common. In the search for genes that predispose to familial breast and ovarian cancer much recent progress has been made. A locus on the long arm of chromosome 17, in the interval 17q12-21, has been identified by genetic linkage, and appears to be responsible for disease in approximately 40 % of breast cancer families and most families that contain breast and ovarian cancer. The region containing this locus, which has been called BRCA1, has been narrowed to a 3-4 cM interval defined by THRA1, the thyroid hormone receptor locus alpha, and D17S183, an anonymous microsatellite polymorphism. Loci other than BRCA1 that have been identified appear not only to predispose to breast and/or ovarian tumors, but to tumors at other sites too. A new locus has been identified on chromosome 2 which is linked to hereditary non-polyposis colorectal cancer (HNPCC). Families with HNPCC are also at risk of endometrial cancer and tumors of the ovary, amongst other cancer sites. Finally, mutations in the p53 gene are inherited in families with Li-Fraumeni syndrome, a rare cancer syndrome predisposing to breast tumors, sarcomas, leukemia and other cancers. Li-Fraumeni syndrome is also the only inherited cancer syndrome that predisposes at least in part to breast cancer where the actual predisposing gene is known. For the other cancer syndromes, the cloning of the predisposing genes is eagerly awaited.


2013 ◽  
Vol 40 (3) ◽  
pp. 475-512 ◽  
Author(s):  
Dana Meaney-Delman ◽  
Cecelia A. Bellcross

Oncotarget ◽  
2016 ◽  
Vol 7 (11) ◽  
pp. 11959-11971 ◽  
Author(s):  
Javier A. Menendez ◽  
Núria Folguera-Blasco ◽  
Elisabet Cuyàs ◽  
Salvador Fernández-Arroyo ◽  
Jorge Joven ◽  
...  

2020 ◽  
Vol 3 (2) ◽  
pp. 374 ◽  
Author(s):  
Anvesh Rathore ◽  
Subhash Ranjan ◽  
AP Dubey

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e12017-e12017 ◽  
Author(s):  
M. C. Katapodi ◽  
S. L. DeFlon ◽  
K. J. Milliron ◽  
L. L. Northouse ◽  
S. Merajver

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13153-e13153
Author(s):  
Veda Padma Priya Selvakumar ◽  
Shubha Garg ◽  
Jatinder Kaur ◽  
Geeta Kadayaprath ◽  
Nitesh Rohatgi ◽  
...  

e13153 Background: Women with Hereditary breast ovarian cancer have an increased lifetime risk of developing breast, ovarian and other second primary cancers . A number of genes including BRCA 1 & 2 have been implicated in Hereditary Breast Ovarian Cancer. In this background we sought to analyze the genetic pattern of patients who underwent genetic testing as per the NCCN criteria for hereditary breast ovarian cancer syndrome. Methods: All consecutive patients who fit into the NCCN criteria for genetic testing for Hereditary Breast Ovarian Cancer from 2016 to 2018 were referred to our genetic clinic. The data of all the patients who underwent further genetic testing after counselling were collected and analyzed. Results: Out of 155 patients who underwent genetic testing ,131 patients were found eligible for the study.127 were female and 4 were male. There were 27 pathogenic mutations identified while 32 were variants of unknown significance . The remaining 72 were negative for any of the known mutations. 22 were pathogenic for BRCA 1 Mutation , two pathogenic for BRCA 2 and one for TP53 ,PALB2 and ATM each. Out of the 32 VUS, 9 were BRCA 2, 4 in CDH 1, 2 in BRCA1, CHEK2 ,MSH2 and BRIP1 and one each in MLH1, MLH3, ATM, APC, RAD51D, XRCC3, NBN, TP53.Three patients had double VUS reported. BRCA 1 is the most common pathogenic mutation ( 16.79% ) found while BRCA 2 is the most common VUS reported ( 28 %). Conclusions: 20.6 % of eligible patients had pathogenic mutations which is much higher than the western literature. However the VUS rates in Indian population are high 22% owing to a paucity of genetic data of Indian population. Multigene testing helps in identifying other genes asscociated with the Hereditary breast ovarian cancer criteria in addition to BRCA 1 & 2.


Sign in / Sign up

Export Citation Format

Share Document